Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for resisting methicillin-resistant staphylococcus aureus (mrsa)

A technology of anti-methicillin and composition, applied in the directions of drug combination, antibacterial drug, active ingredient of heterocyclic compounds, etc., can solve the problem that the treatment cannot meet the clinical needs, etc., and achieve the effect of preventing and treating infection

Inactive Publication Date: 2015-10-14
CHINA PHARM UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, MRSA with intermediate resistance to vancomycin (VISA) or resistance (VRSA) has appeared in Japan and the United States in recent years, which has brought challenges to the treatment of MRSA with vancomycin.
Therefore, the treatment of MRSA infection with a single antibiotic can no longer meet the clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for resisting methicillin-resistant staphylococcus aureus (mrsa)
  • Pharmaceutical composition for resisting methicillin-resistant staphylococcus aureus (mrsa)
  • Pharmaceutical composition for resisting methicillin-resistant staphylococcus aureus (mrsa)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Cbf-K 16 Effect of combined use with ceftazidime on the death protection rate of MRSA-infected mice

[0048] The experiment uses about 20g of ICR mice, half male and half male, randomly divided into 7 groups, set as blank group, model group, Cbf-K 16 group (40mg / kg / d), ceftazidime group (80mg / kg / d), low dose combination group (Cbf-K 16 20mg / kg / d, ceftazidime 80mg / kg / d), medium-dose combination group (Cbf-K 16 40mg / kg / d, ceftazidime 80mg / kg / d), high-dose combination group (Cbf-K 16 80mg / kg / d, ceftazidime 80mg / kg / d). After 2 days of adaptive culture, the experiment was started. Except for the blank group, mice in other groups were intraperitoneally injected with 5×10 8 CFU of MRSA, Cbf-K 16 0.5h and 2h after infection were administered intraperitoneally, ceftazidime was administered via tail vein at 0h and 6h after infection, the survival status was observed for 7 consecutive days, the number of deaths was recorded, and the death protection rate was calculated.

[...

Embodiment 2

[0053] Cbf-K 16 Effects of combined use with ampicillin on the death protection rate of MRSA-infected mice

[0054] The experiment uses about 20g of ICR mice, half male and half male, randomly divided into 7 groups, set as blank group, model group, Cbf-K 16 group (40mg / kg / d), ampicillin group (80mg / kg / d), low-dose combination group (Cbf-K 16 20mg / kg / d, ampicillin 80mg / kg / d), medium-dose combination group (Cbf-K 16 40mg / kg / d, ampicillin 80mg / kg / d), high-dose combination group (Cbf-K 16 80mg / kg / d, ampicillin 80mg / kg / d). After 2 days of adaptive culture, the experiment was started. Except for the blank group, mice in other groups were intraperitoneally injected with 5×10 8 CFU of MRSA, Cbf-K 16 0.5h and 2h after infection, intraperitoneal administration, ampicillin 0h and 6h after infection tail vein administration, 7 days to observe the survival status, record the number of deaths, and calculate the death protection rate.

[0055] Table 5 Cbf-K 16 and ampicillin on the d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for resisting methicillin-resistant staphylococcus aureus (mrsa). The pharmaceutical composition has an mrsa infection-resistant effect. Ceftazidime and ampicillin have the effect of inhibiting the synthesis of a bacterial cell wall, while cbf-k16 is a cationic antimicrobial peptide and has a cell membrane penetrating effect. The in-vitro antibacterial activity of the peptide cbf-k16 and ceftazidim or ampicillin which are combined to be used is researched by using a chessboard method and a bactericidal curve method, and the result shows that the pharmaceutical composition has remarkable in-vitro synergic mrsa-resistant activity. Meanwhile, in-vivo researches show that the pharmaceutical composition composed of the peptide cbf-k16 and ceftazidim or ampicillin has a remarkable effect on treating animal generalized infection caused by mrsa, and therefore the pharmaceutical composition is proved to have remarkable in-vivo and in-vitro synergic antibacterial activity for mrsa and have a relatively good application prospect on the aspect of clinically treating diseases infected by mrsa.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for synergistically resisting methicillin-resistant Staphylococcus aureus (MRSA) infection, the pharmaceutical composition comprising antimicrobial peptide Cbf-K 16 and an antibiotic selected from ceftazidime or ampicillin. Background technique [0002] Antibiotics have greatly extended human life since they were used in the treatment of bacterial infections. However, with the extensive use of antibiotics, the problem of antibiotic resistance has become increasingly serious, and the rate of bacterial resistance has far exceeded the rate of development of new antibiotics. Staphylococcus aureus is one of the main pathogens of clinical infection, which can cause skin and soft tissue infection, pneumonia, bacteremia, surgical site and catheter-related infection, etc., seriously endangering human health. In the past 20 years, MRSA has become an important pathogen of nosocomial infection and has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/16A61P31/04A61P11/00A61P19/02A61P9/00A61P17/00A61P17/02A61P39/02A61K31/546A61K31/43
Inventor 周长林康玮刘含含李博王嫣蓉窦洁王慧
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com